Demographic and clinical data between groups were compared by chi-squared test and by Student’s t-test. Statistical significance was assumed at the p < 0.05 level. The SPSS for Windows (version 13.0; SPSS, Inc) was used for all of the statistical analysis. Results Subject characteristics The demographics of the cases and controls enrolled in this study are summarized in Table2. There were no statistically significant differences between the cases and controls for the age, menopausal status (P = 0.979 and P = 0.593, respectively), and this suggested LY2109761 clinical trial that the matching based on these two variables
was adequate. Table 2 Characteristics of patients with breast cancer and healthy controls Variable Patients, no. (%) Controls, no. (%) P-value n = 315 n = 322 Age(year) 0.979 < 48 165 (52.4) 169 (52.5) ≥48 150 (47.6) 153 (47.5) Menopausal status 0.593 Premenopausal 144 (45.7) 154 (47.8) selleck chemicals Postmenopausal 171 (54.3) 168 (52.2)
Tumor size (cm) < 2 104 (33.0) 2~5 167 (53.0) ≥5 44 (14.0) LN involvement Positive 117 (37.1) Negative 198 (62.9) ER expression Positive 169 (53.7) Negative 146 (46.3) PR expression Positive 166 (52.7) Negative 149 (47.3) Genotype and allele frequencies The genotype and allele frequencies of the IL-10 gene polymorphisms in breast cancer patients and healthy controls are show in Table3. The genotypes were found to be in Hardy-Weinberg equilibrium in both case and control groups. Statistical analysis, however, revealed no significant Pomalidomide chemical structure differences in the genotype and allele frequencies at all three SNP sites between patients and healthy controls. In addition to overall comparisons, the genotype frequencies were compared in subgroups classified according to menopausal status and no association was found between genotypes and risk of breast cancer. Table 3 Genotype and allele frequencies of IL-10 promoter polymorphisms in breast cancer patients and healthy controls Frequency, no.(%) Frequency, no.(%) Genetype Patients n = 315 Controls n = 322 P -value Alleles
Patients 2n = 630 Controls 2n = 644 P -value -1082 A/G 0.664 -1082 A/G 0.374 AA 285 (90.5) 285 (88.5) A 599 (95.1) 605 (93.9) AG 29 (9.2) 35 (10.9) G 31 (4.9) 39 (6.1) GG 1 (0.3) 2 (0.6) -819 T/C 0.604 -819 T/C 0.315 TT 119 (37.8) 134 (41.6) T 373 (59.2) 399 (62.0) TC 135 (42.9) 131 (40.7) C 257 (40.8) 245 (38.0) CC 61 (19.3) 57 (17.7) -592 A/C 0.604 -592 A/C 0.315 AA 119 (37.8) 134 (41.6) A 373 (59.2) 399 (62.0) AC 135 (42.9) 131 (40.7) C 257 (40.8) 245 (38.0) CC 61 (19.3) 57 (17.7) Analysis of association between genotypes and clinicopathologic features of breast cancer revealed no association between genotypes at these positions and ER expression and PR expression.